Severity Assessment of TR: Impact of GDMT on Imaging Findings and Invasive Hemodynamics
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Equity/Stock(s)/Options - REVAMPMedical
- Consultant Fee/Honoraria/Speaker's Bureau - Abbott; Edwards Lifesciences
- Travel reimbursement - Ancora